Herzschrittmachertherapie und Elektrophysiologie最新文献_第7页

[Characterization of atrial fibrillation burden using wearables]. [利用可穿戴设备确定心房颤动负担的特征]。

Herzschrittmachertherapie und Elektrophysiologie Pub Date : 2024-06-01 Epub Date: 2024-02-09 DOI: 10.1007/s00399-024-00995-2

Konstanze Betz, Dominik Linz, David Duncker, Henrike A K Hillmann

{"title":"[Characterization of atrial fibrillation burden using wearables].","authors":"Konstanze Betz, Dominik Linz, David Duncker, Henrike A K Hillmann","doi":"10.1007/s00399-024-00995-2","DOIUrl":"10.1007/s00399-024-00995-2","url":null,"abstract":"The characterization of atrial fibrillation (AF) according to current guidelines categorically refers to the differentiation between paroxysmal, persistent, and permanent AF. A more precise characterization of AF, including the evaluation of AF burden, is playing an increasingly significant role in both scientific research and clinical practice. Digital devices, especially those with the capability of passive (semi-)continuous recording, can contribute to a more accurate quantification of AF burden. Particularly in patients with an already established diagnosis of AF, the evaluation of AF burden can be used to monitor the success of antiarrhythmic therapy including antiarrhythmic drugs or pulmonary vein isolation. However, important questions remain unanswered: In addition to a uniform, evidence-based definition of AF burden, clinically relevant cut-offs for AF burden and resulting therapeutic consequences (e.g., subclinical AF) need to be elaborated. Furthermore, the establishment and evaluation of care structures for assessing and integrating AF burden in clinical care, especially by incorporating data from wearable medical devices, should take place.","PeriodicalId":52403,"journal":{"name":"Herzschrittmachertherapie und Elektrophysiologie","volume":" ","pages":"111-117"},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11161421/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139708436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Postmortem genetic analysis following sudden cardiac death : Background, approach, and future]. [心脏性猝死的死后基因分析：背景、方法和未来]。

Herzschrittmachertherapie und Elektrophysiologie Pub Date : 2024-03-01 Epub Date: 2024-01-10 DOI: 10.1007/s00399-023-00986-9

Silke Kauferstein, Britt-Maria Beckmann

{"title":"[Postmortem genetic analysis following sudden cardiac death : Background, approach, and future].","authors":"Silke Kauferstein, Britt-Maria Beckmann","doi":"10.1007/s00399-023-00986-9","DOIUrl":"10.1007/s00399-023-00986-9","url":null,"abstract":"Background: Sudden cardiac death (SCD) is defined as an unexpected, nontraumatic death with a possible cardiac or unknown cause. The lowest incidence is observed in infancy and childhood (1 per 100,000), and the incidence is approximately 50 per 100,000 in the middle-aged population, reaching a plateau around the age of 80 (200 per 100,000). While most SCD cases occur in older people with coronary artery disease, there is a predominance of monogenetic and polygenetic diseases in the young.Methods: Postmortem genetic analysis (molecular autopsy) using next-generation sequencing reveals a definite pathogenic genetic alteration, which can explain SCD of young patients in near 20% of the cases. Hence, postmortem genetic analysis has become an important tool to unravel the inheritable cause of death. Furthermore, early identification of a pathogenic genetic sequence variant in the deceased is crucial to reduce risk in relatives due to preventive personalized measures.Results and conclusion: Postmortem genetic analysis forms together with the clinical assessment the basis for early identification of at-risk relatives. A new guideline for the management of ventricular arrhythmias and prevention of sudden death was recently published by the European Society of Cardiology. The new recommendations give genetic testing, also in deceased patients a much higher priority reflecting increasing relevance of genetic testing for diagnostic evaluation, risk stratification and prevention.","PeriodicalId":52403,"journal":{"name":"Herzschrittmachertherapie und Elektrophysiologie","volume":" ","pages":"31-38"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139405187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

More than 30 years of Brugada syndrome: a critical appraisal of achievements and open issues. Brugada 综合征 30 多年：对成就和未决问题的批判性评估。

Herzschrittmachertherapie und Elektrophysiologie Pub Date : 2024-03-01 Epub Date: 2023-12-12 DOI: 10.1007/s00399-023-00983-y

Lars Eckardt, Christian Veltmann

{"title":"More than 30 years of Brugada syndrome: a critical appraisal of achievements and open issues.","authors":"Lars Eckardt, Christian Veltmann","doi":"10.1007/s00399-023-00983-y","DOIUrl":"10.1007/s00399-023-00983-y","url":null,"abstract":"Over the last three decades, what is referred to as Brugada syndrome (BrS) has developed from a clinical observation of initially a few cases of sudden cardiac death (SCD) in the absence of structural heart disease with ECG signs of \"atypical right bundle brunch block\" to a predominantly electrocardiographic, and to a lesser extent genetic, diagnosis. Today, BrS is diagnosed in patients without overt structural heart disease and a spontaneous Brugada type 1 ECG pattern regardless of symptoms. The diagnosis of BrS is less clear in those with an only transient or drug-induced type 1 Brugada pattern, but should be considered in the presence of an arrhythmic syncope, family history of BrS, or family history of sudden death. In addition to survived cardiac arrest, syncope is probably the single most decisive risk marker for future arrhythmias. For asymptomatic BrS, risk stratification remains challenging. General recommendations to lower the risk in BrS include avoidance of drugs/agents known to induce and/or increase right precordial ST-segment elevation, including treatment of fever with antipyretic drugs. Several ECG markers that have been associated with an increased risk of SCD have been incorporated into a recently published risk score for BrS. The aim of this article is to provide an overview of the status of risk stratification and to illustrate open issues und gaps in evidence in BrS.","PeriodicalId":52403,"journal":{"name":"Herzschrittmachertherapie und Elektrophysiologie","volume":" ","pages":"9-18"},"PeriodicalIF":0.0,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138811279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[You can only understand today if you know yesterday : The history of rhythmology in Germany]. [只有了解昨天，才能理解今天：德国韵律学的历史]。

Herzschrittmachertherapie und Elektrophysiologie Pub Date : 2024-03-01 Epub Date: 2024-03-08 DOI: 10.1007/s00399-024-01013-1

M Borggrefe, F de Haan, C W Israel

引用次数: 0

[Genetics in atrial fibrillation and malignant arrhythmia syndromes]. [心房颤动和恶性心律失常综合征的遗传学]。

Herzschrittmachertherapie und Elektrophysiologie Pub Date : 2024-03-01 Epub Date: 2024-02-20 DOI: 10.1007/s00399-024-00998-z

Rainer Schimpf, Ursula Ravens

引用次数: 0

[Perioperative management for cardiovascular implantable electronic devices]. [心血管植入式电子设备的围手术期管理]。

Herzschrittmachertherapie und Elektrophysiologie Pub Date : 2024-03-01 Epub Date: 2024-01-30 DOI: 10.1007/s00399-023-00989-6

Konstantin Krieger, Innu Park, Till Althoff, Sonia Busch, K R Julian Chun, Heidi Estner, Leon Iden, Tilman Maurer, Andreas Rillig, Philipp Sommer, Daniel Steven, Roland Tilz, David Duncker

引用次数: 0

[Historical development of diagnosis of bradyarrhythmias : The early years of clinical electrophysiology in Germany]. [诊断缓慢性心律失常的历史发展：德国临床电生理学的早期发展]。

Herzschrittmachertherapie und Elektrophysiologie Pub Date : 2024-03-01 Epub Date: 2024-02-28 DOI: 10.1007/s00399-024-01006-0

Günter Breithardt

引用次数: 0

[How everything started: the beginning and development of clinical electrophysiology in Germany]. [一切是如何开始的：德国临床电生理学的起步与发展]。

Herzschrittmachertherapie und Elektrophysiologie Pub Date : 2024-03-01 Epub Date: 2024-02-29 DOI: 10.1007/s00399-024-01002-4

Ludger Seipel, Fokko de Haan

引用次数: 0

[Cardiogenetics in Germany- a view and review]. [德国的心脏遗传学--观点与回顾]。

Herzschrittmachertherapie und Elektrophysiologie Pub Date : 2024-03-01 Epub Date: 2024-02-28 DOI: 10.1007/s00399-024-01008-y

E Schulze-Bahr

引用次数: 0

[Genetic basis of atrial fibrillation-on the road to precision medicine]. 【精准医疗之路上心房颤动的遗传基础】。

Herzschrittmachertherapie und Elektrophysiologie Pub Date : 2024-03-01 Epub Date: 2023-11-06 DOI: 10.1007/s00399-023-00974-z

Shinwan Kany, Renate B Schnabel

引用次数: 0